A soluble receptor decoy protects rats against anthrax lethal toxin challenge

Journal of Infectious Diseases

Volumn 192, Issue 6, 2005, Pages 1047-1051

  Scobie, Heather M ^a,c   Thomas, Diane ^b   Marlett, John M ^a   Destito, Giuseppe ^b,e   Wigelsworth, Darran J ^d   Collier, R John ^d   Young, John A T ^a   Manchester, Marianne ^b  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Univ Degli Stud di Reggio Calabria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX ANTITOXIN; ANTHRAX LETHAL TOXIN; ANTHRAX TOXIN; ANTHRAX TOXIN PROTECTIVE ANTIGEN; ANTITOXIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; RECEPTOR; SOLUBLE ANTHRAX TOXIN RECEPTOR; SOLUBLE CAPILLARY MORPHOGENESIS PROTEIN 2; SOLUBLE RECEPTOR DECOY; TUMOR ENDOTHELIAL MARKER 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BINDING AFFINITY; BINDING COMPETITION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNITY; INHALATION; LETHALITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROVOCATION TEST; RAT; RECEPTOR BINDING; STOICHIOMETRY; TISSUE CULTURE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CHO CELLS; CRICETINAE; MALE; MEMBRANE PROTEINS; PROTEIN BINDING; RATS; RATS, INBRED F344; RECEPTORS, PEPTIDE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 24644503512     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432731     Document Type: Article

References (15)

1. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-52.
2. Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol 2003; 19:45-70.
3. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9.
4. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 2003; 100:5170-4.
5. Abrami L, Lindsay M, Parton RG, Leppla SH, Van Der Goot FG. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J Cell Biol 2004; 166:645-51.
6. Rainey GJA, Young JAT. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004; 2:721-6.
7. Sawada-Hirai R, Jiang I, Wang F, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004; 2:5.
8. Sellman BR, Mourez M, Collier RJ. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2001; 292: 695-7.
9. Wild MA, Xin H, Maruyama T, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003; 21:1305-6.
10. Wigelsworth DJ, Krantz BA, Christensen KA, Lacy DB, Juris SJ, Collier RJ. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J Biol Chem 2004; 279:23349-56.
11. Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002; 20:597-601.
12. Rosovitz MJ, Schuck P, Varughese M, et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 2003; 278:30936-44.
13. Mourez M, Yan M, Lacy DB, et al. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci USA 2003; 100:13803-8.
14. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO542. Antimicrob Agents Chemother 2004; 48:423-9.
15. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-79.